Ad
related to: antigen presentation in cancer research- Ways to Give Back
Take action, give today, and
save lives. Learn more here.
- Donate Now
Make a donation to lifesaving
cancer immunotherapy research.
- Why Donate?
We can change the way cancer is
treated and cured. Make an impact.
- What is Immunotherapy?
Unleash the power of the immune
system to fight cancer.
- Ways to Give Back
Search results
Results from the WOW.Com Content Network
Dedicated antigen-presenting cells, including macrophages, B cells and dendritic cells, present foreign antigens to helper T cells, while virus-infected cells (or cancer cells) can present antigens originating inside the cell to cytotoxic T cells. In addition to the MHC family of proteins, antigen presentation relies on other specialized ...
Artificial antigen presenting cells (aAPCs) are engineered platforms for T-cell activation. aAPCs are used as a new technology and approach to cancer immunotherapy. Immunotherapy aims to utilize the body's own defense mechanism—the immune system —to recognize mutated cancer cells and to kill them the way the immune system would recognize ...
Antigen presentation is a vital immune process that is essential for T cell immune response triggering. Because T cells recognize only fragmented antigens displayed on cell surfaces , antigen processing must occur before the antigen fragment can be recognized by a T-cell receptor .
Antigens encoded by cancer-germline genes such as MAGEA1 and MAGEA3 have been used in the form of antigenic peptide, protein or recombinant viruses harbouring a sequence coding for the antigen. Clinical responses have been observed in a small minority (< 10%) of patients.
Tumor antigen is an antigenic substance produced in tumor cells, i.e., it triggers an immune response in the host. Tumor antigens are useful tumor markers in identifying tumor cells with diagnostic tests and are potential candidates for use in cancer therapy .
Since the MR1 molecule is involved in presentation of cancer specific antigens and plays a role in tumor immunosurveillance, it has potential use in immunotherapy. [21] Specific clones of MR1 T lymphocytes (MC.7.G5) were able to kill various cancer cells in vivo and in vitro and were inert to noncancerous cells.
Once the exogenous antigen peptide is loaded onto the MHC class I molecule, the complex is exported to the cell surface for antigen cross presentation. There is also evidence that suggest that cross-presentation requires a separate pathway in a proportion of CD8(+) dendritic cells that are able to cross-present.
Tumor-associated immune cells in the tumor microenvironment (TME) of breast cancer models. Cancer immunology (immuno-oncology) is an interdisciplinary branch of biology and a sub-discipline of immunology that is concerned with understanding the role of the immune system in the progression and development of cancer; the most well known application is cancer immunotherapy, which utilises the ...
Ad
related to: antigen presentation in cancer research